AgomAb Therapeutics NV American Depositary Shares Total Liabilities
AgomAb Therapeutics NV American Depositary Shares total liabilities. Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has total liabilities worth $18.70 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See AGMB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of AgomAb Therapeutics NV American Depositary Shares (2021–2025)
Total liabilities of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025. This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data. Check AgomAb Therapeutics NV American Deposita (AGMB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
AgomAb Therapeutics NV American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SVI Public Company Limited
BK:SVI
|
Thailand | ฿6.89 Billion |
|
Analyst IMS Investment Management Services Ltd
TA:ANLT
|
Israel | ILA229.18 Million |
|
Focus Minerals Ltd
AU:FML
|
Australia | AU$74.65 Million |
|
Northeast Community Bancorp Inc
NASDAQ:NECB
|
USA | $1.75 Billion |
|
Aprogen KIC Inc
KO:007460
|
Korea | ₩323.51 Billion |
|
China Lilang Limited
F:5LX
|
Germany | €2.28 Billion |
|
Kretam Holdings Bhd
KLSE:1996
|
Malaysia | RM243.03 Million |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
China | CN¥420.92 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down AgomAb Therapeutics NV American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AgomAb Therapeutics NV American Deposita (AGMB) total assets.
Liquidity & Leverage Metrics
AgomAb Therapeutics NV American Depositary Shares Total Liabilities Ratios Explained
AgomAb Therapeutics NV American Depositary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AgomAb Therapeutics NV American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AgomAb Therapeutics NV American Depositary Shares (2021–2025)
The table below shows the annual total liabilities of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $22.80 Million | +24.77% |
| 2024-12-31 | $18.28 Million | -7.80% |
| 2023-12-31 | $19.82 Million | -42.95% |
| 2022-12-31 | $34.75 Million | -16.54% |
| 2021-12-31 | $41.63 Million | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinica… Read more